Ganglioneuroblastoma Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Ganglioneuroblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled175 locationsNCT06172296
Recruiting
Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NeuroblastomaGanglioneuroblastoma, NodularGanglioneuroblastoma
Children's Oncology Group750 enrolled162 locationsNCT03126916
Recruiting
Phase 3

Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

Neuroblastoma (NB)Ganglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology5 enrolled1 locationNCT07375563
Recruiting
Not Applicable

Phase II Study of Proton Radiation Therapy for Neuroblastoma

NeuroblastomaGanglioneuroblastoma
Massachusetts General Hospital30 enrolled1 locationNCT02112617
Recruiting
Not Applicable

SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours

NeuroblastomaGanglioneuromaGanglioneuroblastoma
Institut Curie600 enrolled38 locationsNCT05192980
Recruiting

Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification

NeuroblastomaGanglioneuromaGanglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology200 enrolled1 locationNCT06296732
Recruiting
Phase 3

Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology15 enrolled1 locationNCT06071897